Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANNEXA-RS: Andexanet alfa vs usual care for urgent surgery in patients on factor Xa inhibitors
jRCT2071230071Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised trial of andexanet alfa in Bleeding (2 arms), sponsored by AstraZeneca. Primary endpoint: Number of patients achieving effective intraoperative hemostasis. Started Nov 2023; status: completed.
02
Drugs
andexanet alfa
03
Conditions
Bleeding
Beyond the preview
Go deeper on jRCT2071230071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230071.